Nudge Spotlight Nudge.ai Account Briefs
ED471901-4303-4CC6-BB60-61574FD72DB7 Created with sketchtool.
Eisai Pharmaceuticals Account Brief
Eisai is a human health care (hhc) company seeking innovative solutions in disease prevention, cure, and care of the health and well-being of people worldwide. The ability to conduct basic and clinical research in the United States strengthens Eisai's resources in the pharmaceutical market and helps the company meet highly competitive research and development goals, enhancing Eisai's proven ability to discover new medicines. Research facilities in the United States include Eisai Research Institute in Andover, Massachusetts; Eisai Medical Research Inc. in Ridgefield Park, New Jersey; and Eisai Inc.'s Research Triangle Park facility in North Carolina.
Eisai Pharmaceuticals Recent News Mentions
news.sys-con.com Jun. 18, 2019
Eisai To Present Latest Data On Perampanel At 33Rd International Epilepsy Congress
Eisai Co., Ltd. announced today that the latest data on its antiepileptic drug (AED) perampanel (product name: Fycompa) will be presented at the 33rd International Epilepsy Congress (IEC) to be held from June 22 to 26, 2019 in Bangkok, Thailand. As major presentations, 2 oral presentations will be given including on the final analysis of a Phase III clinical study (Study 311) on adjunctive perampanel in pediatric patients aged 4 to less than 12 years old with epilepsy. Also, a total of 12 poster presentations will be given, including on the primary analysis from a Phase III clinical study (FREEDOM / Study 342), which was conducted in Japan and South Korea, on the efficacy and safety of perampanel monotherapy in untreated epilepsy patients with partial-onset seizures (with or without secondary generalized seizures). Perampanel is a first-in-class AED and a once-daily tablet discovered at Eisai's Tsukuba Research Laboratories. In the United States and Europe, an oral suspension formulation has been approved and is being marketed. The agent is a highly selective, noncompetitive AMPA receptor antagonist that reduces neuronal hyperexcitation by targeting glutamate activity at AMPA receptors on postsynaptic membranes. Perampanel is currently approved in countries around the world as an adjunctive therapy for the treatment of partial-onset seizures (with or without secondary generalized seizures) and primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older. Furthermore, in the United States, Perampanel is approved for monotherapy and adjunctive use in the treatment of partial-onset seizures (with or without secondary generalized seizures) in patients with epilepsy 4 years of age and older. Eisai considers neurology including epilepsy, a therapeutic area of focus, and strives to deliver perampanel throughout the world in pursuit of our mission to provide "seizure freedom" to a greater number of patients living with epilepsy. Eisai seeks
See 3 more news mentions
Executives and decision-makers at Eisai Pharmaceuticals
Nudge.ai’s relationship intelligence platform can help you find the right executive to reach out to at Eisai Pharmaceuticals, such as Pat Forsythe, General Manager, or Paul Hawthorne, Senior Vice President, Americas Commercial. Then get in touch and start a conversation.
Pat Forsythe General Manager
Get in touch
Paul Hawthorne Senior Vice President, Americas Commercial
Get in touch
Eric Foster Vice President, Program And Alliance Management
Get in touch
Douglas Snyder Vice President And General Counsel
Get in touch
Evelyn D Shen Associate General Counsel, Intellectual Property
Get in touch
Neriman Botas Exec Vp Hr & Corp Communications
Get in touch
Jack Markey Senior Director
Get in touch
Neil West Vice President EMEA, Global Neurology Business Unit
Get in touch
Alex Scott Senior Vice President, Corporate Development
Get in touch
Shaji Procida President & COO
Get in touch
See 5 more decision makers
Connectors at Eisai Pharmaceuticals
Executives can be difficult to reach, but every company has connectors who bring together people and ideas. At Eisai Pharmaceuticals, people like Cynthia Schwalm, and David Trexler are likely connectors.
Cynthia Schwalm
Ask for intro
David Trexler
Ask for intro
Teresa Cronin Director, Corporate Advocacy
Ask for intro
See who in your network has relationships at Eisai Pharmaceuticals With Nudge.ai you can uncover which contacts at a company your network is most strongly connected to. If you find a strong relationship, ask for an introduction!
Topics frequently mentioned alongside Eisai Pharmaceuticals
When Eisai Pharmaceuticals is mentioned in the news, Nudge.ai often sees topics like Europe, and Leadership. If your conversation focuses on these topics, you’ll probably get Eisai Pharmaceuticals’s attention.
Europe
Leadership
Health
Acting
Search
Product
Biotech
Growth
Companies frequently mentioned alongside Eisai Pharmaceuticals
When Eisai Pharmaceuticals is mentioned in the news, companies such as PR Newswire, Abbvie, and Nomura Securities International are often also mentioned. These companies can serve as customer examples.
Executives Get in touch with decision-makers at Eisai Pharmaceuticals. Sign up for Nudge Premium to:
See who in your network can offer a warm intro
Get insights on the company's key decision-makers
Start 30-day free trial now
Connectors Ask connectors at Eisai Pharmaceuticals for intros to execs. Sign up for Nudge Premium to:
See who in your network can offer a warm intro to connectors
Leverage your network to find pathways into new companies
Start 30-day free trial now
Recent News Don't waste time researching your targets. Sign up for Nudge Premium to:
Get notified when your target accounts are mentioned in the news
Get insights on target companies right within your inbox as you write emails
Start 30-day free trial now